From India, Singapore, South Korea and Israel
Suven Life Sciences has secured four product patents from India, Singapore, South Korea and Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2031, 2034, 2034 and 2036 respectively.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content